CA
GILD icon

Continental Advisors’s Gilead Sciences GILD Stock Holding History

Continental Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$1.72M – 55
2022
Q4 		$1.72M Buy
+20,000
New +$1.58M 0.9% 38

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Continental Advisors's GILD Position: Q2 2026 in Review

Continental Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 28,367 shares worth $3.58M. The position accounts for 1.51% of the portfolio, ranked #24.

Continental Advisors first reported a position in GILD in Q3 2016 and has held it in 40 quarters since. The position peaked at $8.53M in Q2 2021. 2,277 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Continental Advisors held 28,367 shares of Gilead Sciences worth $3.58M as of Q2 2026.
  • Continental Advisors left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 1.51% of Continental Advisors's portfolio in Q2 2026, its #24 holding.
  • Continental Advisors first reported a position in Gilead Sciences in Q3 2016 and has held it in 40 quarters since.
  • Continental Advisors's Gilead Sciences position peaked at $8.53M in Q2 2021.
  • 2,277 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Continental Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.